---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025273"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:38:28.239784+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics closes $6.9M public offering with full over-allotment exercise

## Summary
- Gross proceeds of $6.9M from 1,922,764 common stock units and 1,528,000 pre-funded warrant units.
- Each unit priced at $2.00 (common) or $1.999 (pre-funded); Series I warrants exercisable at $2.00 for 5 years.
- Underwriters exercised 450,000-unit over-allotment option in full; Ladenburg Thalmann sole book-runner.
- Proceeds for working capital, pre-clinical studies, and clinical trial preparation.
- Directors and executive officers subject to 90-day lock-up agreements post-closing.

## SEC filing metadata
- accession: 0001641172-25-025273
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225025273/0001641172-25-025273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225025273/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025273
- JSON: https://secwatch.observer/filing/0001641172-25-025273.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.